GET DAILY SIGNALSCompugen (CGEN) Shares Fall -13% Over 30 Days as Catalyst Timeline Extends
Key Takeaways
- Compugen shares declined roughly 13% over the past 30 days, moving from about $2.31 to approximately $2.01 as of early November 2026.
- The pullback extended a broader slide, with the stock down roughly 15% over the last quarter from its early-August levels near $2.38.
- Compugen remains a clinical-stage cancer immunotherapy company built around its AI-powered Unigen computational discovery platform and a pipeline spanning COM701, rilvegostomig, and GS-0321.
- A key near-term catalyst gap is a factor: the MAIA-ovarian interim analysis for COM701 is not expected until the first quarter of 2027.
- Third-quarter 2026 financial results are scheduled for release on November 9, 2026.
Compugen (CGEN) Company Background and Pipeline Focus
Compugen Ltd. is a clinical-stage cancer immunotherapy company based in Holon, Israel, with shares listed on both Nasdaq and the Tel Aviv Stock Exchange. What sets it apart is Unigen, an AI/ML-powered computational platform designed to uncover new drug targets and advance immuno-oncology candidates. The pipeline centers on COM701, a potential first-in-class anti-PVRIG antibody in the MAIA-ovarian adaptive platform trial; rilvegostomig, a PD-1/TIGIT bispecific antibody under an exclusive license with AstraZeneca; and GS-0321, a potential first-in-class anti-IL-18 binding protein antibody licensed to Gilead. Collaborations with AstraZeneca and Gilead could deliver up to approximately $1 billion in milestone payments plus royalties, while the company has reported a cash runway expected to support operations into 2029.
CGEN Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, CGEN shares moved from a closing level of approximately $2.31 on October 5, 2026, to about $2.01 by early November 2026, a decline of roughly 13%. The path was uneven, with the stock drifting lower through much of October, touching an intraday low near $1.87 in late October before a modest recovery into the $2.00 range heading into November. I also checked this using Tickeron’s AI Pattern Search Engine to compare recent price action with historical patterns.
Over the broader quarter, the stock started near $2.38 in early August, reached an intraday peak around $2.87 in late August, and then gave back those gains through September and October. The net result is a decline of roughly 15% from early-August levels, reflecting initial optimism around the pipeline followed by a re-rating lower.
Factors Behind the Recent 30-Day Decline in CGEN
The 30-day drop occurred during a relatively quiet period for clinical updates. The most important upcoming readout, the MAIA-ovarian interim analysis for COM701, is not expected until the first quarter of 2027, leaving the stock without a near-term binary event to sustain momentum. The company held a virtual KOL event on COM701 and the Unigen platform in early October and joined an AI-based drug discovery conference, yet these did not stem the selling. Technical factors also mattered, with the stock trading below its 200-day moving average near $2.30 and hovering just above prior post-earnings lows. Broader caution toward small-cap biotech names added pressure as investors waited for clearer pipeline progress. A partial rebound late in the period aligned with announcements of upcoming investor conferences and the scheduled third-quarter earnings release.
Quarterly Performance Drivers for Compugen Stock
The quarterly trend shows a shift from momentum to caution. CGEN rallied sharply in late August on optimism around AstraZeneca’s expanding Phase 3 program for rilvegostomig and the wider potential of the COM701 franchise, only to retreat steadily as investors factored in the longer wait for the MAIA-ovarian interim data. Sentiment was also influenced by the company’s clinical-stage profile, where revenue is modest and tied to partner milestones. The cash balance stood at approximately $125.3 million at the end of June 2026, providing runway but underscoring the extended timeline to the next major internal catalyst in 2027.
Key Items on the Horizon for CGEN Investors
Several elements are likely to influence CGEN in the coming months. Third-quarter 2026 results, due November 9, 2026, will provide updates on cash, spending, and timelines. The MAIA-ovarian interim analysis for COM701 in the first quarter of 2027 stands as the largest near-term data catalyst. AstraZeneca’s ongoing Phase 3 work with rilvegostomig could affect the value of Compugen’s royalty and milestone rights. Progress on Gilead’s GS-0321 Phase 1 program and any data timelines may also move sentiment. Broader conditions in small-cap biotechnology and clinical enrollment rates remain external variables worth monitoring.
Exploring AI Tools for Market Analysis
In my own research process I occasionally turn to Tickeron’s AI Trading Bots to test how automated strategies are approaching names in the biotech space. The platform provides a range of virtual agents with different timeframes and objectives, which helps me compare signals against my own views on timing and risk. It is one more data point when evaluating opportunities like the current setup in CGEN. Visit AI Trading Bots to review the available strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
CGEN's RSI Indicator climbs out of oversold territory
The RSI Indicator for CGEN moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 39 of the 44 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where CGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CGEN just turned positive on October 28, 2026. Looking at past instances where CGEN's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
Following a +3.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 190 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGEN as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CGEN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.146) is normal, around the industry mean (3.051). P/E Ratio (5.289) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of drug and diagnostics
Industry Biotechnology
Advertisement